Mozooni Zahra, Amiri Kiana Khajeh, Golestani Nafiseh, Shahmohammadi Alireza, Minaeian Sara, Bahadorizadeh Leyla
Antimicrobial Resistance Research Center, Institute of Immunology, and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Department of Internal Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ann Coloproctol. 2025 Apr;41(2):136-144. doi: 10.3393/ac.2024.00227.0032. Epub 2025 Apr 29.
Colorectal cancer (CRC) is the most common malignancy of the gastrointestinal system globally. Identifying specific gene expression patterns indicative of early-stage CRC could enable early diagnosis and rapid treatment initiation. Matrix metalloproteinases (MMPs) play crucial roles in extracellular matrix degradation and tissue remodeling. Among them, MMP-2 and MMP-9 have been found to be upregulated in various cancers, including CRC, and are associated with tumor invasion, metastasis, and angiogenesis. In contrast, a disintegrin and metalloproteinase like decysin 1 (ADAMDEC1) is a relatively newly discovered gene with demonstrated involvement in immune response and inflammation. This study investigated serum levels of MMP-2 and MMP-9, along with tissue expression of MMP-2, MMP-9, and ADAMDEC1, and explored potential associations with pathological and clinical factors in patients with CRC.
This study included 100 patients with CRC and 100 control participants. Tissue and blood samples were collected. Serum MMP-2 and MMP-9 levels were analyzed using the enzyme-linked immunosorbent assay. Quantitative real-time polymerase chain reaction was employed to assess the expression levels of MMP-2, MMP-9, and ADAMDEC1 in CRC tissue samples compared to adjacent control tissue.
The expression levels of MMP-2, MMP-9, and ADAMDEC1 were significantly upregulated in CRC relative to adjacent control tissues. Analysis of clinicopathological features revealed statistically significant differences in the expression levels of MMP-2, MMP-9, and ADAMDEC1 between patients with CRC with and without lymphovascular invasion (P<0.001). Based on receiver operating characteristic curve analysis, these genes represent promising candidate diagnostic biomarkers for CRC.
MMP-2, MMP-9, and ADAMDEC1 levels may serve as potential diagnostic biomarkers for CRC.
结直肠癌（CRC）是全球胃肠道系统最常见的恶性肿瘤。识别指示早期CRC的特定基因表达模式能够实现早期诊断并迅速开始治疗。基质金属蛋白酶（MMPs）在细胞外基质降解和组织重塑中起关键作用。其中，MMP-2和MMP-9已发现在包括CRC在内的各种癌症中上调，并与肿瘤侵袭、转移和血管生成相关。相比之下，去整合素和金属蛋白酶样蛋白1（ADAMDEC1）是一个相对新发现的基因，已证明其参与免疫反应和炎症。本研究调查了MMP-2和MMP-9的血清水平，以及MMP-2、MMP-9和ADAMDEC1的组织表达，并探讨了与CRC患者病理和临床因素的潜在关联。
本研究纳入100例CRC患者和100名对照参与者。收集组织和血液样本。使用酶联免疫吸附测定法分析血清MMP-2和MMP-9水平。采用定量实时聚合酶链反应评估CRC组织样本中MMP-2、MMP-9和ADAMDEC1的表达水平，并与相邻对照组织进行比较。
与相邻对照组织相比，CRC中MMP-2、MMP-9和ADAMDEC1的表达水平显著上调。临床病理特征分析显示，有和无淋巴管浸润的CRC患者之间，MMP-2、MMP-9和ADAMDEC1的表达水平存在统计学显著差异（P<0.001）。基于受试者工作特征曲线分析，这些基因是CRC有前景的候选诊断生物标志物。
MMP-2、MMP-9和ADAMDEC1水平可能作为CRC的潜在诊断生物标志物。
